ABBOTT LABORATORIES Stock Repurchases 2007-2026 | ABT
Beta
What is stock repurchases?
Stock repurchases (buybacks) represent cash spent to buy back the company's own shares from the open market, returning capital to shareholders.
What is ABBOTT LABORATORIES's current stock repurchases?
ABBOTT LABORATORIES (ABT) annual stock repurchases for 2025 was $893.0M, a 31.04% decline from 2024. ABBOTT LABORATORIES stock repurchases for the quarter ending March 31, 2026 was $180.0M.
What was ABBOTT LABORATORIES's stock repurchases in 2024?
ABBOTT LABORATORIES annual stock repurchases for 2024 was $1.29B, a 5.54% increase from 2023.
What was ABBOTT LABORATORIES's stock repurchases in 2023?
ABBOTT LABORATORIES annual stock repurchases for 2023 was $1.23B, a 67.67% decline from 2022.
What is ABBOTT LABORATORIES's 5-year stock repurchases CAGR?
ABBOTT LABORATORIES stock repurchases grew at a compound annual growth rate (CAGR) of 17.25% from FY2020 to FY2025, going from $403.0M to $893.0M over 5 years.
Stock Repurchases History
Year-over-year comparison from 10-K annual reports
Key Statistics
Trend Direction
Stable
CAGR+17.2%
FY2020
$403.0M
→
FY2025
$893.0M
07080910111213141516171819202122232425
5 years selected
Stock Repurchases History
| Period | Value | Change | Source |
|---|---|---|---|
| FY2025 | $893.0M | -31.0% | 10-K |
| FY2024 | $1.29B | +5.5% | 10-K |
| FY2023 | $1.23B | -67.7% | 10-K |
| FY2022 | $3.79B | +65.1% | 10-K |
| FY2021 | $2.30B | +470.5% | 10-K |
| FY2020 | $403.0M | -43.9% | 10-K |
| FY2019 | $718.0M | +201.7% | 10-K |
| FY2018 | $238.0M | +103.4% | 10-K |
| FY2017 | $117.0M | -77.6% | 10-K |
| FY2016 | $522.0M | -76.7% | 10-K |
| FY2015 | $2.24B | +1.9% | 10-K |
| FY2014 | $2.19B | +36.8% | 10-K |
| FY2013 | $1.60B | -32.1% | 10-K |
| FY2012 | $2.36B | +2970.1% | 10-K |
| FY2011 | $77.0M | -91.1% | 10-K |
| FY2010 | $866.8M | +4.9% | 10-K |
| FY2009 | $826.3M | -23.6% | 10-K |
| FY2008 | $1.08B | +2.2% | 10-K |
| FY2007 | $1.06B | - | 10-K |
Company: ABBOTT LABORATORIESTicker: ABTSector: HealthcareIndustry: Pharmaceutical PreparationsView company profile →